Evidence map›Paper›PMID 42780650›Full record

ArticleFrontiers in bioengineering and biotechnology2026

A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.

Lorea Jordana-Urriza, Manuele G Muraro, Marc Du, Victoria Lambrecht, Juan Roberto Rodriguez-Madoz, Ivan Martin, Andrés García-García

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lorea Jordana-UrrizaHemato-Oncology Program. Cima Universidad de Navarra. IdiSNA, Pamplona, Spain.
Manuele G MuraroTissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Marc DuTissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Victoria LambrechtTissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Juan Roberto Rodriguez-MadozHemato-Oncology Program. Cima Universidad de Navarra. IdiSNA, Pamplona, Spain.
Ivan MartinTissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Andrés García-GarcíaTissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antigen (BCMA) have shown unprecedented success in treating multiple myeloma (MM), yet long-term relapse remains a critical challenge, possible due to the protective influence of the bone marrow (BM) microenvironment. Current

Indexed as

3D osteogenic nichebone marrowCAR T cellimmunotherapymultiple myeloma

Identifiers

PMID42780650
PMCPMC13597705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.